AVEO Oncology (AVEO) Tops Q3 EPS by 6c; Reports Cash and Cash Equivalents of $94.0M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
November 8, 2021 4:05 PM EST
Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $14.3 Million
Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab)
Ficlatuzumab and ERBITUX® (cetuximab) Granted Fast Track Designation by the U.S. FDA for R/R HNSCC; Potential Registrational Clinical Trial Expected to Commence in 1H 2023
Company to Host Conference Call Today at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the third quarter ended September... More
